AIQ

AIQ Global is a private healthcare technology and medical device company focused on AI-enabled quantitative imaging for oncology. Its lead product, TRAQinform IQ, is an FDA-cleared software medical device that analyzes lesion-level changes across serial scans to characterize heterogeneous treatment response, particularly in advanced and metastatic cancer. The company emerged from translational imaging research at the University of Wisconsin and positions its technology for both clinical decision support and use in biopharma-sponsored clinical studies. AIQ has published and presented data across prostate cancer, melanoma, lymphoma, lung cancer, and immuno-oncology settings. The business appears to be commercial-stage with active U.S. and Australia operations.